More about

Alopecia

News
July 03, 2024
1 min read
Save

Eirion Therapeutics initiates phase 1 trial for ET-02 for androgenic alopecia treatment

Eirion Therapeutics initiates phase 1 trial for ET-02 for androgenic alopecia treatment

The first participant has been enrolled in Eirion Therapeutics’ phase 1 study evaluating the safety of ET-02 for the treatment of androgenic alopecia, the company announced in a press release.

News
June 11, 2024
1 min read
Save

Oral contraceptive pill usage may be associated with frontal fibrosing alopecia

Oral contraceptive pill usage may be associated with frontal fibrosing alopecia

Women who use contraceptive pills may be at a higher risk for frontal fibrosing alopecia, according to a study.

News
June 05, 2024
1 min read
Save

EQ101 demonstrates favorable efficacy, tolerability for treatment of alopecia areata

EQ101 demonstrates favorable efficacy, tolerability for treatment of alopecia areata

Equillium announced positive topline data from its phase 2, single-dose, proof-of-concept study of EQ101 for the treatment of adults with moderate, severe or very severe alopecia areata, according to a press release.

News
May 31, 2024
1 min read
Save

Topical STS-01 demonstrates promising phase 2 results for alopecia areata treatment

Topical STS-01 demonstrates promising phase 2 results for alopecia areata treatment

Soterios Pharma has announced positive topline results from its phase 2 trial evaluating STS-01 for the treatment of mild to moderate alopecia areata, according to a company press release.

News
May 18, 2024
1 min read
Save

NIH awards Mount Sinai $6.6 million to research dupilumab as pediatric alopecia treatment

NIH awards Mount Sinai $6.6 million to research dupilumab as pediatric alopecia treatment

The NIH has awarded Emma Guttman-Yassky, MD, PhD, a $6.6 million grant to investigate dupilumab as a treatment for children with alopecia areata, Mount Sinai announced in a press release.

News
April 26, 2024
2 min read
Save

Researchers conclude continual use of ritlecitinib safe in alopecia areata

Researchers conclude continual use of ritlecitinib safe in alopecia areata

Ritlecitinib was well tolerated and safe when continually used to treat alopecia areata in patients aged 12 years and older, according to a study.

CME
Multimedia

Alopecia Areata in Children and Adolescents: More Than Just Skin Deep

Alopecia Areata in Children and Adolescents: More Than Just Skin Deep
0.75 CME
0.75 AAPA
45 MINS
$0 FEE
News
April 21, 2024
1 min watch
Save

VIDEO: AAD session shares social media pearls for dermatology

VIDEO: AAD session shares social media pearls for dermatology

In this Healio exclusive video, Ronda S. Farah, MD, FAAD, talks about a session at this year’s American Academy of Dermatology Annual Meeting on addressing misinformation on social media and tips for dermatologists.

News
April 19, 2024
2 min read
Save

Low-dose oral minoxidil shows similar results to topical treatment in alopecia

Low-dose oral minoxidil shows similar results to topical treatment in alopecia

Low-dose oral minoxidil was similarly efficacious as the drug’s topical version in male androgenetic alopecia, according to a study.

News
March 28, 2024
2 min read
Save

Most prescribers favor oral minoxidil for androgenetic alopecia

Most prescribers favor oral minoxidil for androgenetic alopecia

Prescribers have expressed an overall positive opinion toward the off-label use of low-dose oral minoxidil for the treatment of androgenetic alopecia, though opinions varied based on years of experience, according to a study.

View more